2023
Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults
Kopel H, Nguyen V, Boileau C, Bogdanov A, Winer I, Ducruet T, Zeng N, Bonafede M, Esposito D, Martin D, Rosen A, Van de Velde N, Vermund S, Gravenstein S, Mansi J. Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults. Vaccines 2023, 11: 1711. PMID: 38006043, PMCID: PMC10675676, DOI: 10.3390/vaccines11111711.Peer-Reviewed Original ResearchCOVID-19-related hospitalizationRelative vaccine effectivenessOutpatient visitsPrimary care electronic health recordsCOVID-19-related outcomesVaccine-induced protectionMedical claims dataCOVID-19 vaccineSARS-CoV-2Electronic health recordsVaccine effectivenessVaccine recipientsMRNA vaccinesBivalent vaccineBaseline differencesStudy populationClaims dataOmicron variantComparative effectivenessHospitalizationPropensity scoreVaccineOlder adultsHealth recordsVisitsPopulation-Level Effectiveness of an Inactivated Whole-Virion COVID-19 Vaccine: A Test Negative Case-Control Study in the Dominican Republic
Pérez-Then E, Miric M, Qian H, Chen Y, Wang Y, Vallejo V, Quezada W, Flaquer M, Olivo J, Castillo J, García N, Calderón K, Cueto S, Veras B, Russo M, Jiménez I, Guzmán S, Garabito L, Cueto E, Colombo F, Taveras D, Torres D, Baez J, Yunen J, Koenig E, Pérez E, López O, Medina F, Wang X, Shao Y, Vermund S, Díaz G, Severino F, Acevedo A, Luciano J, Cuello J, Acevedo I, Espinál M, Martínez C, Díaz D, Espinál D, Almonte D, Rodríguez J, Rosa J, Reyes J, Fernández J, De Jesús Marte Mercado M, De Los Santos Carmona R, Liriano R, Heyliger A, Mejía A, Turbis A, Aquino C, José E, Del Rosario Y, Rosario C, Hermón J, Colón A, Flores A, Díaz C, Rodríguez D, Estrella J, Colón J, Reyes J, Gil L, Abbott M, de Mota M, Polanco N, Jiménez I, Santana R, Herrera S, Castellanos A, Germosén A, Fajardo F, Mercedes K, Méndez M, F S, Sánchez T, Payano Y, Gómez Y, Mejía Y, Sánchez D, Infante H, Grullón M, Lemos Y, Carpio P, Pineda C, Núñez M, Espiritusanto D, Álvarez G, Nina G, Cabrera K, Guerrero R, Mejía B, Nicolás K, Guante M, Lebrón M, Bidó M, Monción M, Brito E, Rosado S, de apoyo P, de Sosa A, Pimentel B, Feliciano D, de los Santos L, Morillo M, Mateo P, de la Cruz R, de los Ángeles García M, Tavárez Y, Luna R, Castillo Y, Ulloa E, Pérez E. Population-Level Effectiveness of an Inactivated Whole-Virion COVID-19 Vaccine: A Test Negative Case-Control Study in the Dominican Republic. Open Forum Infectious Diseases 2023, 10: ofad075. PMID: 36998630, PMCID: PMC10043129, DOI: 10.1093/ofid/ofad075.Peer-Reviewed Original ResearchSymptomatic SARS-CoV-2 infectionTest-negative case-control studyCOVID-19-related hospitalizationSARS-CoV-2 infectionCase-control studyCOVID-19 vaccineFull vaccinationAssisted ventilationPartial vaccinationLower oddsAcute respiratory syndrome coronavirus 2 infectionCoronavirus disease 2019 (COVID-19) vaccination programsInactivated COVID-19 vaccineNegative case-control studySyndrome coronavirus 2 infectionPositive polymerase chain reaction testCOVID-19-related symptomsNationwide vaccination campaignPCR-positive participantsCoronavirus 2 infectionReal-world effectivenessPolymerase chain reaction testPopulation-level effectivenessSARS-CoV-2Chain reaction test
2022
Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
Pérez-Then E, Lucas C, Monteiro VS, Miric M, Brache V, Cochon L, Vogels CBF, Malik AA, De la Cruz E, Jorge A, De los Santos M, Leon P, Breban MI, Billig K, Yildirim I, Pearson C, Downing R, Gagnon E, Muyombwe A, Razeq J, Campbell M, Ko AI, Omer SB, Grubaugh ND, Vermund SH, Iwasaki A. Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination. Nature Medicine 2022, 28: 481-485. PMID: 35051990, PMCID: PMC8938264, DOI: 10.1038/s41591-022-01705-6.Peer-Reviewed Original ResearchConceptsTwo-dose regimenOmicron variantVaccine boosterMRNA vaccinesNeutralization activityDelta variantTwo-dose mRNA vaccinesVirus-specific antibody levelsSARS-CoV-2 Omicron variantMRNA vaccine boosterNeutralization of OmicronNumerous spike mutationsSARS-CoV-2 DeltaPotent neutralization activityInfection-induced immunityCOVID-19 vaccineBNT162b2 boosterBooster vaccinationPrime vaccinationAntibody levelsAntibody titersHumoral immunityImmune escapeInactivated vaccinesVaccine